SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

2 marketing jobs

Viatris logo
1 month ago

Director, Global Marketing – Cenerimod

Viatris

Torrington, WY (Remote)Full time$112K/yr – $236K/yr
Viatris logo
2 months ago

Senior Director, Digital Marketing

Viatris

USA (Remote)Full time$151K/yr – $314K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

2 jobs
Viatris logo

Director, Global Marketing – Cenerimod

Viatris

Torrington, WY (Remote)

$112K/yr - $236K/yrIn-houseFull-timeDirector/executive10+ years exp.
1 month ago
Viatris logo

Senior Director, Digital Marketing

Viatris

USA (Remote)

$151K/yr - $314K/yrIn-houseFull-timeSenior level8+ years exp.
2 months ago
Viatris logo
Viatris

Director, Global Marketing – Cenerimod

Torrington, WY (Remote)

$112K/yr – $236K/yrDirector/Executive10+ years expFull time

Posted 1 month ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the global brand story from evidence-driven positioning through launch readiness and cross-functional governance, shaping the strategy, budgets, and regional localization while translating data into value messages for access and medical audiences.

  • Brand Leadership: Own the global vision, GBP, and annual brand planning with cross-team alignment.
  • Launch & Evidence: Lead pre launch, Phase 3 narrative, and publication planning with access framing.
  • Governance & Collaboration: Govern brand standards, vendor relationships, and GLRT with regional partners.

Job Description

  • Define and evolve the global brand vision, positioning, and value proposition based on scientific evidence and market insights.
  • Develop and manage the Global Brand Plan (GBP), including long-range forecasts, strategic imperatives, and tactical priorities.
  • Lead the annual brand planning process, ensuring alignment across global and regional teams.
  • Provide brand governance and ensure alignment with corporate portfolio and therapeutic area strategies.
  • Lead pre-launch activities including market shaping, disease awareness, and competitive intelligence initiatives.
  • Partner with Medical Affairs to build the scientific narrative and prepare for data dissemination at key congresses.
  • Oversee unbranded disease campaigns, early stakeholder engagement, and external communication frameworks.
  • Establish global standards for launch readiness tracking, including KPIs and milestone dashboards.
  • Translate Phase 3 clinical data into compelling, compliant brand narratives and commercial communication tools.
  • Collaborate with Clinical and Medical functions on publication planning and evidence-to-value translation.
  • Bachelor’s degree in Life Sciences, Business, or related field required.
  • Advanced degree (MBA, MSc, PharmD, or equivalent) preferred.
  • Minimum 10 years of pharmaceutical or biotech marketing experience, including global or regional leadership roles.
  • However, a combination of experience and/or education will be taken into consideration.
  • Proven success in pre-launch or launch preparation for specialty or immunology products.
  • Demonstrated experience in cross-functional collaboration within a matrixed organization.
  • Solid understanding of drug development, clinical data interpretation, and evidence-based communication.
  • Prior experience in autoimmune or rare diseases strongly preferred.
  • Strong strategic and analytical skills with ability to synthesize complex data into actionable plans.
  • Excellent leadership, interpersonal, and influencing capabilities across functions and geographies.
  • Experience with autoimmune or rare diseases.
  • Competitive salaries, benefits and an inclusive environment.
Viatris logo

Viatris

3.8 Glassdoor

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, IndiaSocial Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelinesInvestors: https://investor.viatris.comCorporate Social Responsibility: https://www.viatris.com/sustainability Connect with ViatrisInstagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisincViatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Founded in 2020
Pittsburgh, Pennsylvania, USA
18K employees (825 in marketing)
www.viatris.com/en
72% recommend to a friend
88% CEO approval

Traffic Signals

Monthly Visitors
81.6K
Traffic Source Mix
Search
49.8%
Direct
34.7%
Referral
11.2%
Social
2.4%
Paid
1.7%

Headcount Trend

Current headcount: ~17.6K

Marketing Team

Marketing Team Size
685 (4% of company)
Marketing Roles Posted (Last 30 Days)
3

Recent News

Viatris signs agreements with Biocon on $815m stake sale
Dec 8, 2025 • Yahoo Finance
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Dec 6, 2025 • PR Newswire
Viatris to Participate in Upcoming Investor Conferences
Nov 24, 2025 • Yahoo Finance
European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for Europe
Nov 19, 2025 • PR Newswire
How Recent Developments Are Rewriting the Story for Viatris
Nov 13, 2025 • Yahoo Finance
Viatris (VTRS) Jumps 10% on Reaffirmed Growth Targets
Nov 12, 2025 • Yahoo Finance
How Upgraded Guidance and Capital Returns at Viatris (VTRS) Have Changed Its Investment Story
Nov 8, 2025 • Yahoo Finance
Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say
Nov 6, 2025 • Yahoo Finance
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
Nov 6, 2025 • PR Newswire
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance - November 6, 2025
Nov 6, 2025 • Zacks Investment Research
Countdown to Viatris (VTRS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Nov 5, 2025 • Yahoo Finance
Viatris Announces Quarterly Dividend
Nov 4, 2025 • Yahoo Finance
Viatris Announces Quarterly Dividend
Nov 4, 2025 • PR Newswire
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
Oct 30, 2025 • Yahoo Finance
Is Viatris (VTRS) Stock Undervalued Right Now?
Oct 28, 2025 • Nasdaq
What You Need to Know Ahead of Viatris' Earnings Release
Oct 24, 2025 • Yahoo Finance
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Oct 21, 2025 • Yahoo Finance
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
Oct 16, 2025 • Zacks Investment Research
How Recent Developments Are Reshaping the Viatris Investment Story
Oct 16, 2025 • Yahoo Finance
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
Oct 16, 2025 • Nasdaq
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
Oct 15, 2025 • PR Newswire
Does Viatris Offer Opportunity After Recent European Approval Boost?
Oct 9, 2025 • Yahoo Finance
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row
Oct 8, 2025 • PR Newswire
Viatris’ Work To Advance Access and Public Health
Oct 7, 2025 • Yahoo Finance
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025
Oct 1, 2025 • Yahoo Finance
Asia Pacific Enterprise Awards (APEA) 2025 Taiwan Honors Outstanding Leaders and Enterprises Shaping the Future of Business
Sep 26, 2025 • prnasia.com
Viatris: Indore Plant Could Boost 2026 Numbers (NASDAQ:VTRS)
Sep 25, 2025 • Seeking Alpha
Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection
Sep 23, 2025 • Yahoo Finance
Cyclosporine Market Size to Hit USD 9.44 Billion by 2032, Driven by Rising Organ Transplants and Expanding Therapeutic Applications | S&S Insider
Sep 23, 2025 • SNS Insider pvt ltd
Viatris Inc.(NasdaqGS:VTRS) dropped from FTSE All-World Index
Sep 22, 2025 • MarketScreener
Germany Iron Deficiency Anemia Therapy Market Size to Worth USD 830.14 Million by 2034
Sep 17, 2025 • Precedence Research
Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection
Sep 17, 2025 • Mapi Pharma
"Celebrate!" Great Place To Work™ Greater China Celebrates the Best Workplaces™ in Taiwan 2025
Sep 12, 2025 • prnasia.com
Viatris Investors Face Skeptical Judges on Biosimilars Unit (1)
Sep 10, 2025 • Bloomberg Law News
'Land mines everywhere': How pharma communications keep up under a political spotlight
Sep 10, 2025 • FiercePharma
WCM-Q brings together international experts on diabetic neuropathy
Sep 9, 2025 • Zawya.com
Colorado must face Teva's lawsuit over free allergy pen law
Sep 5, 2025 • Reuters
Analysts’ forecast returns, recommendations and yields for all stocks in the S&P 500
Sep 5, 2025 • Globe and Mail
Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris
Sep 4, 2025 • Yahoo Finance
Top 8 richest person in Karnataka in 2025: Businessman with Rs 1.07 lakh crore net worth beats Nikhil Kamath and Narayana Murthy for #1 spot
Sep 3, 2025 • Indian Express
Epinephrine Market to Size to Reach USD 5.74 Billion by 2032 as Demand for Emergency Allergy Treatments Surges – SNS Insider
Sep 1, 2025 • SNS Insider pvt ltd
Viatris (VTRS) Valuation in Focus After Creation of New Chief Administrative and Transformation Officer Role
Aug 30, 2025 • simplywall.st
Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health
Aug 29, 2025 • Yahoo Finance
Anaphylaxis Treatment Market to Reach $11.6 Billion by 2033 | Driven by Allergies, Auto-Injectors & R&D
Aug 28, 2025 • EIN Presswire
OneSource CEO On Next-Gen GLP-1 Innovator Talks, Xbrane And Viatris Partnering
Aug 22, 2025 • insights.citeline.com
Revenues rise and losses narrow as Shield Therapeutics as US sales deliver major boost
Aug 22, 2025 • Business Live
Pediatric Asthma Treatment Market Anticipated to Grow at 0% CAGR Through 2029: Industry Report
Aug 22, 2025 • EIN Presswire
Primary Biliary Cholangitis Therapeutics Global Market Report 2025| Business Growth, Current and Future Trends till 2029
Aug 22, 2025 • EIN Presswire
Orally Disintegrating Tablet Market Report 2025 | Growth Drivers, Trends, and Outlook Forecast Through 2029
Aug 22, 2025 • EIN Presswire
By 2030, the global liver disease treatment market is forecasted to achieve $36.45 billion, expanding at a CAGR of 5.7%.
Aug 20, 2025 • EIN Presswire
Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment
Aug 19, 2025 • Yahoo Finance
Viatris names Andrew Enrietti as chief administrative officer
Aug 19, 2025 • Investing.com
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
Aug 19, 2025 • PR Newswire
Viatris Inc. Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
Aug 19, 2025 • MarketScreener
Viatris names Andrew Enrietti Chief Administrative and Transformation Officer
Aug 19, 2025 • thefly.com
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
Aug 19, 2025 • citybiz
Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth
Aug 14, 2025 • Research and Markets
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call
Aug 13, 2025 • Yahoo Finance
Viatris CEO Smith buys $219k in company stock
Aug 13, 2025 • Investing.com
CSL's Venofer finally faces generic competition as FDA clears copycats from Viatris, Sandoz and Amphastar
Aug 13, 2025 • FiercePharma
Endocarditis Market Global and Regional Analysis and Forecast Report 2025-2035 Featuring Pfizer, Teva, Viatris, Fresenius Kabi, Basilea, Phaxiam, Hikma, Advacare, and Sandoz - ResearchAndMarkets.com
Aug 13, 2025 • Business Wire
Viatris first to win US approval for generic Venofer
Aug 12, 2025 • Pharma Letter
Why Viatris (VTRS) Stock Is Up Today
Aug 11, 2025 • Yahoo Finance
Viatris stock rises after FDA approval of first generic iron sucrose
Aug 11, 2025 • Investing.com
Carpmaels and A&O Shearman file first SPC suit at UPC for Merz against Viatris
Aug 11, 2025 • JUVE Patent
Merz Asks UPC To Bar Viatris Generic MS Drug
Aug 11, 2025 • Law360
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
Aug 11, 2025 • PR Newswire
Viatris announces FDA approval for Iron Sucrose Injection
Aug 11, 2025 • thefly.com
Biocon Biologics posts strong Q1 growth as North America, Europe deliver
Aug 9, 2025 • Livemint.com
Viatris To Seek FDA Approval For MR-141 In Presbyopia In 2H, 2025 - Did The Stock Catch Your Eye?
Aug 8, 2025 • RTTNews
Europe Viscosupplementation Market Projected To Witness Substantial Growth, 2025-2032:Sanofi S.A., Anika Therapeutics
Aug 8, 2025 • EIN Presswire
Airway Clearance Devices Market Set to Grow at an Impressive CAGR of 5.04% Through 2034 | 8.34 USD Billion
Aug 8, 2025 • EIN Presswire
Viatris aims for top-half 2025 revenue and EPS guidance while advancing late-stage pipeline
Aug 7, 2025 • MSN
Viatris Surpasses Q2 2025 Revenue Expectations
Aug 7, 2025 • TipRanks
Earnings call transcript: Viatris beats Q2 2025 estimates, stock rises
Aug 7, 2025 • Investing.com
Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates
Aug 7, 2025 • Yahoo Finance
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
Aug 7, 2025 • Zacks Investment Research
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
Aug 7, 2025 • Viatris
Postoperative Pain Management Market Poised for Transformation During the Forecast Period (2025–2034) with Rising Non-Opioid Adoption | DelveInsight
Aug 7, 2025 • DelveInsight Business Research LLP
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
Aug 7, 2025 • BioSpace
Viatris reports Q2 adjusted EPS 62c, consensus 56c
Aug 7, 2025 • thefly.com
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
Aug 7, 2025 • PR Newswire
Viatris backs FY25 adjusted EPS view $2.16-$2.30, consensus $2.22
Aug 7, 2025 • thefly.com
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Aug 6, 2025 • Yahoo Finance
Viatris (VTRS) Reports Earnings Tomorrow: What To Expect
Aug 5, 2025 • Yahoo Finance
Viatris Stock: Analyst Estimates & Ratings
Aug 5, 2025 • Barchart.com
Viatris Announces Quarterly Dividend
Aug 5, 2025 • PR Newswire
Viatris Announces Appointment of David Simmons to the Company's Board of Directors
Aug 5, 2025 • Viatris
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
Aug 4, 2025 • Nasdaq
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
Aug 4, 2025 • Zacks Investment Research
Post-Traumatic Stress Disorder Treatment Market to Reach $26.1 Billion, Globally, by 2031 at 4.9% CAGR
Aug 4, 2025 • EIN Presswire
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
Aug 1, 2025 • PR Newswire
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
Aug 1, 2025 • BioSpace
Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health
Jul 31, 2025 • Research and Markets
‘The regulatory environment is always evolving,’ says this expert
Jul 29, 2025 • Silicon Republic
Chiesi, Viatris among collaborators on BIO's latest BBC-produced video series
Jul 28, 2025 • FiercePharma
Global Herpes Simplex Virus Treatment Market: Growth, Trends, and Opportunities to 2031
Jul 28, 2025 • EIN Presswire
10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts
Jul 26, 2025 • Morningstar.com
Liatris Inc. Expands Pilot Facility for High-Performance Insulation With more than $1 Million in State and Local Investment
Jul 25, 2025 • PRWeb
Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case
Jul 25, 2025 • Benzinga.com